Conversion of paid subscribed units (BTU) to shares and warrants of series 2021

Dicot AB (publ) ("Dicot" or the "Company") has conducted a rights issue of approximately SEK 21.8 million (the "Rights Issue"). The Rights Issue was subscribed with 326 percent. In total, 5,453,576 units were issued in the Rights Issue consisting of 21,814,304 shares and 21,814,304 warrants of series 2021 (TO2).

The Rights Issue has now been registered with the Swedish Companies Registration Office. The last day of trading in paid subscribed units (BTU) is July 6, 2020. The record day for conversion is July 8, 2020, after which BTU will be converted to shares and warrants of series 2021.

Shares and warrants issued in the Rights Issue are estimated to be available on subscribers' custody/vp-accounts on July 10, 2020.

The first day of trading in warrants of series 2021 is estimated to be July 10, 2020.

The warrants of series 2021 that have been issued through the Rights Issue entitle the holder to subscribe for one (1) new share in Dicot during the subscription period from March 17, 2021 through March 31, 2021. The subscription price for shares using the warrants will correspond to 70 percent of the volume weighted average price of the Company's shares according to the Spotlight Stock Market official price list for the period from March 1, 2021 through March 15, 2021 but will not be higher than SEK 2.00 or less than SEK 0.125 (corresponding to the quota value of the Company's shares).

Following the Rights Issue, the Company has 38,175,032 shares and the Company's share capital is SEK 4,771,879.

ISIN-code for shares in Dicot: SE0011178458

ISIN-code for BTU in Dicot: SE0014429411

ISIN-code for TO2 in Dicot: SE0014429379

Advisors
Mangold Fondkommission AB is acting as financial adviser to the Company in the Rights Issue. Advokatfirman Lindahl KB is acting as the legal adviser to the Company.

For further information, please contact:

Göran Beijer, CEO
Tel: +46 (0) 706 63 60 09
E-mail: [email protected]
www.dicot.se

About Dicot AB                                                                     

Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients' lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company's lead product, Libiguin™, for the treatment of sexual dysfunctions, is in a stage of pre-clinical development. Dicot is listed on the Spotlight Stock Market and has approximately 700 shareholders. For more information see www.dicot.se.

Important information

This press release is not an offer to subscribe for shares or units in Dicot and investors should not subscribe or acquire any securities. Invitation to concerned persons to subscribe for shares in Dicot will only be made through the EU growth prospectus.

This press release shall not, directly or indirectly, be released, published or distributed in or to the United States, Australia Japan, Canada, New Zealand, Hong Kong, South Africa or in any other country where the Rights Issue or distribution of the press release is in violation of applicable laws or regulations or presupposes that a further prospectus is established, registered or that any other measure is undertaken beyond that required by Swedish law where such action as a whole or in part is subject to legal restrictions.

Neither unit rights, units subscribed for ("BTU") or newly issued units have been recommended or approved by any US federal or state securities authority or regulatory authority. No subscription rights, BTA or newly issued shares have been registered or will be registered under the United States Securities Act of 1933, or under the securities law of any state in the United States. Therefore, no new shares, paid subscribed shares, subscription rights or other securities issued by the Company may be transferred, exercised or offered for sale in the United States other than in such exceptional cases that do not require registration or through a transaction that is not covered by such registration. There is no intention to register any portion of the offer in the United States and the securities issued in the Rights Issue will not be offered to the public in the United States.

The Company has not authorized any offer to the public with regards to the shares or rights that are referred to in this communication in any member state of the European Economic Area (''EEA'') besides Sweden. This communication is only addressed to and is only directed at qualified investors in other members states within the EEA member state and in the United Kingdom.

Nerladdningsbara filer

European Association of Urology har valt ut Dicots studieresultat för presentation

Uppsala, 21 december 2021. Läkemedelsföretaget Dicot meddelar att resultaten som visar effekt av Dicots läkemedelskandidat i en sjukdomsmodell kommer att presenteras på European Association of Urology's (EAU) årliga kongress 2022, i Amsterdam.


European Association of Urology has selected Dicot's study result to be presented

Uppsala, December 21, 2021. The pharmaceutical company Dicot announces that the results showing effect of Dicot's drug candidate in a disease animal model will be presented at the European Association of Urology's (EAU) annual congress 2022 in Amsterdam.


Dicots studieresultat presenteras på ledande vetenskaplig kongress

Pressmeddelande: Uppsala, 6 december 2021. Läkemedelsföretaget Dicot meddelar att resultaten som visar effekten av Dicots läkemedelskandidat kommer att presenteras på European Society for Sexual Medicine's (ESSM) årliga kongress i Rotterdam i februari 2022.


Dicot's study results to be presented at leading scientific congress

Press release: Uppsala, December 6, 2021. The pharmaceutical company Dicot announces that the results of Dicot's drug candidate will be presented at the European Society for Sexual Medicine's (ESSM) annual congress in Rotterdam in February 2022.


Dicots potensläkemedelskandidat visar effekt och lång duration även vid låg dosering

Pressmeddelande: Uppsala, 2 december 2021. Dicots senaste djurstudie visar att läkemedelskandidaten LIB-01 har effekt även vid en låg dos samt att 7 dagars duration av effekt på erektil funktion har konfirmerats. Det ger goda förutsättningar inför kommande kliniska studier på människa.


Dicot's potency drug candidate demonstrates efficiency and long duration even at a low dose

Press release: Uppsala, December 2, 2021. Dicot's latest animal study demonstrates effect of the drug candidate LIB-01 even at low dose and the 7-day duration of effect on erectile function was confirmed, which provides solid ground for coming clinical studies in humans.


Information om valberedning i Dicot AB

Uppsala, 22 november 2021. Enligt det beslut om valberedningen som fattades vid årsstämman i Dicot AB den 25 maj 2021 ska valberedningen inför årsstämman den 24 maj 2022 bestå av tre ledamöter representerande de tre största aktieägarna per den sista september 2021. För det fall någon av de tre största aktieägarna inte önskar utse en ledamot av valberedningen ska den fjärde största aktieägaren tillfrågas (och så vidare) intill dess att valberedningen består av tre ledamöter.


Dicots företrädesemission är registrerad - omvandling av BTU till aktier och teckningsoptioner samt upptagande till handel av teckningsoptioner

Uppsala, 22 november 2021. Dicot AB (publ) ("Dicot" eller "Bolaget") har genomfört en företrädesemission av units om cirka 25,3 MSEK, som avslutades den 27 oktober 2021 ("Företrädesemissionen"). Företrädesemissionen tecknades till totalt 97,9 procent. Genom Företrädesemissionen tillförs Bolaget cirka 24,7 MSEK före emissionskostnader.


Dicot's rights issue is registered - paid subscription units (BTU) are converted to shares and warrants, and trading of warrants commences

Uppsala, November 22, 2021. Dicot AB (publ) ("Dicot" or the "Company") has carried out a rights issue of units to an amount of approximately MSEK 25.3 ("the Rights Issue"). The Rights Issue was completed on October 27, 2021. The Rights Issue was subscribed to 97.9 percent. Through the Rights Issue, the Company obtains approximately MSEK 24.7 before issue costs.


Dicot AB Delårsrapport januari - september 2021

Pressmeddelande: Uppsala, 18 november 2021. Dicot ABs (publ) delårsrapport för januari - september 2021 finns nu tillgänglig på bolagets hemsida www.dicot.se.


Summary of Interim Report January - September 2021, Dicot AB

Press release: Uppsala, November 18, 2021. A summary of the Interim report January - September 2021, for Dicot AB (publ) is now available on the company website www.dicot.se 


Dicots företrädesemission tecknades till cirka 98 procent

Uppsala, 1 november 2021. Företrädesemissionen om 25,3 MSEK som offentliggjordes den 8 september 2021 och som godkändes av extra bolagsstämman den 6 oktober 2021 ("Företrädesemissionen") i Dicot AB (publ) ("Dicot" eller "Bolaget") blev nästan fulltecknad. Företrädesemissionen tecknades till totalt 97,9 procent. Genom Företrädesemissionen tillförs Bolaget cirka 24,7 MSEK före emissionskostnader.


Dicot's rights issue is subscribed with approx. 98 percent

Uppsala, November 1, 2021. The rights issue of SEK 25.3 million which was disclosed on September 8, 2021 and resolved by the extra general meeting on October 6, 2021 (the "Rights Issue")  in Dicot AB (publ) ("Dicot" or the "Company") has almost been fully subscribed. The Rights Issue was subscribed to 97.9percent. Through the Rights Issue, the Company obtains approximately SEK 24.7 million before issue costs.


Med anledning av positiva studieresultat offentliggör Dicot tilläggsprospekt

Pressmeddelande: Uppsala, 20 oktober 2021. Med anledning av att Dicot AB ("Dicot" eller "Bolaget") den 14 oktober 2021 offentliggjorde positiva resultat från en avslutad studie under den pågående teckningsperioden i Bolagets förestående företrädesemissionen av units har Bolaget nu upprättat ett tilläggsprospekt ("Tilläggsprospektet") till det EU-tillväxtprospekt som godkändes och registrerades av Finansinspektionen den 8 oktober 2021 ("Prospektet"). Tilläggsprospektet - som godkändes av Finansinspektionen idag den 20 oktober 2021 - är en del av och ska läsas tillsammans med Prospektet.


Due to positive study results Dicot publishes a supplement prospectus

Press release: Uppsala, October 20, 2021. On October 14, 2021 Dicot AB ("Dicot" or the "Company") published positive results from a completed study. Since that publication was made during the subscription period in the ongoing unit rights issue the Company has now established a supplement prospectus (the "Supplement") to the EU growth prospectus related to the invitation to subscribe for units in Dicot with preferential rights which was approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) (''SFSA'') on October 8, 2021 (hereinafter, the "Prospectus"). The Supplement - which was approved by the Swedish Financial Supervisory Authority today October 20, 2021 - forms a part of the Prospectus and shall in all respects be read together with the Prospectus.



Studie av djur med diabetes visar på effekt hos Dicots läkemedelskandidat

Pressmeddelande: Uppsala, 14 oktober 2021. Potensläkemedelsutvecklaren Dicot har precis avslutat en studie på råttor med diabetes och bevisad erektil dysfunktion. Bolagets läkemedelskandidat demonstrerade signifikant förbättrad erektion jämfört med kontrollgruppen.


Study of animals with diabetes shows effect in Dicot's drug candidate

Press release: Uppsala, October 14, 2021. Potency drug developer Dicot has just completed a study on rats with diabetes and proven erectile dysfunction. The company's drug candidate demonstrated significantly improved erections compared to vehicle.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted